For Immediate Release
Chicago, IL – April 17, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Comcast CMCSA, Bristol-Myers Squibb BMY, Walgreens Boots Alliance WBA, UnitedHealth Group UNH and Xcel Energy XEL.
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Comcast, Bristol Myers and Walgreens
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Comcast, Bristol-Myers Squibb and Walgreens Boots Alliance. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Comcast’s shares have underperformed the Zacks Cable Television industry over the past six months (-18.8% vs. -11%). The Zacks analyst believes that Comcast is benefiting from solid high-speed Internet customer wins.
The company’s strategy to provide high-speed Internet at an affordable price plays a pivotal role in improving customer experience. Moreover, its Internet business is expected to gain traction from strong demand as more and more people stay at home due to the coronavirus outbreak. Increased media consumption and work-from-home wave bode well for Comcast.
Growing popularity of Xfinity and Flex products is also a major catalyst. Additionally, Sky’s content strength is expected to drive the subscriber base in Europe. However, Comcast continues to lose video subscribers due to cord cutting. Theme Parks remain closed on account of the coronavirus spread. Higher debt level is also a key concern.
Shares of Bristol-Myers have gained 31.4% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of 9.3%. The Zacks analyst believes that Bristol-Myers’ blockbuster immuno-oncology drug, Opdivo, maintains momentum.
Blood thinner drug, Eliquis, has propelled sales significantly and is expected to drive further growth, owing to increased share in the NOAC market. Empliciti and Sprycel are also performing well on label expansions. Meanwhile, the acquisition of Celgene has strengthened the company’s oncology portfolio with the addition of Revlimid and its pipeline with encouraging candidates.
However, concerns will rise once Revlimid loses patent protection. Moreover, the company is facing headwinds like stiff competition from other immuno-oncology drugs and pipeline setbacks.
Walgreens’ shares have lost 19.9% over the past three months against the Zacks Drug Stores industry’s fall of 20.8%. The Zacks analyst believes that the uptick in Retail Pharmacy USA came from comparable prescription sales growth and a strong retail prescription market. Rise in Pharmaceutical Wholesale sales buoy optimism too.
Walgreens Boots posted better-than-expected second-quarter fiscal 2020. Amid the coronavirus-led doldrums, these businesses recorded sales growth on rising customer demand. Progress made from new strategic partnerships was impressive.
However, decline in adjusted earnings is concerning. Dullness in the Retail Pharmacy International was due to poor testing market conditions. Also, the company did not update its guidance, given the pandemic’s rapidly changing variables. Tough market conditions, margin pressure and stiff competitive landscape are other headwinds for the company.
Other noteworthy reports we are featuring today include UnitedHealth Group and Xcel Energy.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Comcast Corporation (CMCSA) : Free Stock Analysis Report
Xcel Energy Inc. (XEL) : Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research